Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Lonza Greenwood LLC has 9 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 9 examiners across 6 art units, indicating a wide examination footprint and limited concentration around any one examiner. Portfolio management will therefore depend on consistent technical positions, reliable status tracking, and careful separation of examiner-specific issues.
PRAGANI, RAJAN is the busiest examiner with 1 pending action. No examiner has a dominant share of the listed workload, so counsel should prioritize cross-matter consistency rather than rely on a single relationship or recurring examiner practice. A coordinated review of claim terminology and biotechnology support can help prevent unnecessary divergence while preserving tailored responses.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (38%) |
| §112 only | 3 (38%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ATKINSON, JOSHUA ALEXANDER | 1 | 51.8% | +27.5% |
| MEAH, MOHAMMAD Y | 1 | 70.7% | +42.8% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
| MCCLAIN, TYNESHA L. | 1 | 15.7% | +24.3% |
| WILLIAMS, EMMALEE RAE | 1 | 0.0% | +0.0% |
| HA, JULIE | 1 | 75.7% | +44.1% |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
| MARTINEZ, TARA L | 1 | 62.7% | +65.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18144542 | METHOD OF MANUFACTURE AND PASTEURIZATION OF PRODUCTS CONTAINING UNDENATURED COLLAGEN | MCCLAIN, TYNESHA L. | 16d overdue |
| 18009359 | Undenatured Type II Collagen as a Supplement for Improved Endurance, Lipid Metabolism, and Oxidative Stress | WILLIAMS, EMMALEE RAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572983 | Method to Control Administration of Active Substance to the Digestive Tract | LEE, SIN J | 43d overdue |
| 18144542 | METHOD OF MANUFACTURE AND PASTEURIZATION OF PRODUCTS CONTAINING UNDENATURED COLLAGEN | MCCLAIN, TYNESHA L. | 16d overdue |
| 17908015 | Undenatured Type II Collagen in Food and Beverage Applications and Uses Thereof | HA, JULIE | 7d |
| 16106348 | Composition and Nutritional Supplement Made Therefrom | MARTINEZ, TARA L | 70d |
| 18833977 | Fast Acting Joint Health Composition and Use Thereof | ATKINSON, JOSHUA ALEXANDER | — |
| 18701644 | Chondroprotective Nutraceutical Composition and Method of Using Same | MEAH, MOHAMMAD Y | — |
| 17260360 | Collagen and Cell Matter Supplement and Method for Administering Same | AUDET, MAURY A | — |
| Art Unit | Apps |
|---|---|
| 1654 | 3 |
| 1612 | 1 |
| 1613 | 1 |
| 1793 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833977 | Fast Acting Joint Health Composition and Use Thereof | ATKINSON, JOSHUA ALEXANDER | 1612 | §102§103§112DP | Non-Final OA | — | Pending | Jul 29, 2024 |
| 18701644 | Chondroprotective Nutraceutical Composition and Method of Using Same | MEAH, MOHAMMAD Y | — | §112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18572983 | Method to Control Administration of Active Substance to the Digestive Tract | LEE, SIN J | 1613 | §103 | Final Rejection | 43d overdue | Pending | Dec 21, 2023 |
| 18144542 | METHOD OF MANUFACTURE AND PASTEURIZATION OF PRODUCTS CONTAINING UNDENATURED COLLAGEN | MCCLAIN, TYNESHA L. | 1793 | §103 | Final Rejection | 16d overdue | Pending | May 08, 2023 |
| 18009359 | Undenatured Type II Collagen as a Supplement for Improved Endurance, Lipid Metabolism, and Oxidative Stress | WILLIAMS, EMMALEE RAE | 1600 | §102§103§112 | Non-Final OA | — | Pending | Dec 09, 2022 |
| 17908015 | Undenatured Type II Collagen in Food and Beverage Applications and Uses Thereof | HA, JULIE | 1654 | §112 | Non-Final OA | 7d | Pending | Aug 30, 2022 |
| 17260360 | Collagen and Cell Matter Supplement and Method for Administering Same | AUDET, MAURY A | 1654 | §103 | Non-Final OA | — | Pending | Jan 14, 2021 |
| 16106348 | Composition and Nutritional Supplement Made Therefrom | MARTINEZ, TARA L | 1654 | §112 | Non-Final OA | 70d | Pending | Aug 21, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLonza Greenwood LLC has 8 pending office actions as of October 2026, spread across 5 art units and 8 examiners.
Joshua Alexander Atkinson has the most, with 1 of Lonza Greenwood LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
